JP2022166228A - ケロイドまたは肥厚性瘢痕の予防または治療用組成物 - Google Patents
ケロイドまたは肥厚性瘢痕の予防または治療用組成物 Download PDFInfo
- Publication number
- JP2022166228A JP2022166228A JP2022130528A JP2022130528A JP2022166228A JP 2022166228 A JP2022166228 A JP 2022166228A JP 2022130528 A JP2022130528 A JP 2022130528A JP 2022130528 A JP2022130528 A JP 2022130528A JP 2022166228 A JP2022166228 A JP 2022166228A
- Authority
- JP
- Japan
- Prior art keywords
- fabp5
- annexin
- eif
- keloids
- prrc1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001969 hypertrophic effect Effects 0.000 title claims abstract description 68
- 231100000241 scar Toxicity 0.000 title claims abstract description 65
- 210000001117 keloid Anatomy 0.000 title claims description 51
- 208000002260 Keloid Diseases 0.000 title claims description 50
- 206010023330 Keloid scar Diseases 0.000 title claims description 19
- 239000000203 mixture Substances 0.000 title claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 100
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 57
- 230000014509 gene expression Effects 0.000 claims abstract description 52
- 208000032544 Cicatrix Diseases 0.000 claims abstract description 42
- 230000037387 scars Effects 0.000 claims abstract description 42
- 102100030421 Fatty acid-binding protein 5 Human genes 0.000 claims abstract description 31
- 101001062855 Homo sapiens Fatty acid-binding protein 5 Proteins 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 108060002900 Filamin Proteins 0.000 claims abstract description 11
- 102000013366 Filamin Human genes 0.000 claims abstract description 11
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 11
- 102000000412 Annexin Human genes 0.000 claims abstract description 4
- 108050008874 Annexin Proteins 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 43
- 210000001519 tissue Anatomy 0.000 claims description 39
- 101001136768 Homo sapiens Protein PRRC1 Proteins 0.000 claims description 32
- 101000653788 Homo sapiens Protein S100-A11 Proteins 0.000 claims description 32
- 102100036553 Protein PRRC1 Human genes 0.000 claims description 32
- 102100029811 Protein S100-A11 Human genes 0.000 claims description 32
- 101000773122 Homo sapiens Thioredoxin domain-containing protein 5 Proteins 0.000 claims description 30
- 102100030269 Thioredoxin domain-containing protein 5 Human genes 0.000 claims description 30
- 102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 claims description 29
- 108010001498 Galectin 1 Proteins 0.000 claims description 29
- 102000000795 Galectin 1 Human genes 0.000 claims description 29
- 108010085279 eukaryotic translation initiation factor 5A Proteins 0.000 claims description 29
- 102000004149 Annexin A2 Human genes 0.000 claims description 27
- 108090000668 Annexin A2 Proteins 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 22
- 239000009180 Flamin Substances 0.000 claims description 20
- 239000002679 microRNA Substances 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 11
- 239000004055 small Interfering RNA Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- -1 Crispr-cas9 Proteins 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 6
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 6
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 230000037390 scarring Effects 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 108091070501 miRNA Proteins 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 108091027757 Deoxyribozyme Proteins 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 abstract description 10
- 108010035532 Collagen Proteins 0.000 abstract description 10
- 229920001436 collagen Polymers 0.000 abstract description 10
- 206010052428 Wound Diseases 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 102000007563 Galectins Human genes 0.000 abstract 1
- 108010046569 Galectins Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 108700011259 MicroRNAs Proteins 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000003197 gene knockdown Methods 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000003449 preventive effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108050006400 Cyclin Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000283070 Abies balsamea Species 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000258957 Asteroidea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004858 Canada balsam Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000016089 mRNA destabilization Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(a)ケロイド組織またはケロイド細胞に試験物質を処理する段階;および
(b)前記試験物質が処理された組織または細胞で細胞内TXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の活性または前記タンパク質をコードする遺伝子の発現量を分析する段階であって、正常組織での前記タンパク質の活性またはこれをコードする遺伝子の発現様相と異なる場合、前記試験物質をケロイドまたは肥厚性瘢痕の予防または治療物質と判断することができる。
ヒト皮膚線維芽細胞、正常組織および肥厚性瘢痕組織の準備
実験に使用した皮膚組織は、総3人の患者から獲得し、男女の正常と瘢痕(scar)組織を利用してIHCを進め、各組織に由来した初代線維芽細胞(primary fibroblast cell)を利用してsiRNA形質転換による効果を観察した。
Biopsyで得られた組織をO.C.T compound(Cell Poth,KMA-0100-00A)を入れ、ドライアイスに入れて凍結した。凍結した組織をアセトンとメタノールが1:1で含有されたバッファーで固定した。バッファーの除去後、0.5%Triton X-100を常温で10分間処理してpermeabilizationさせた後、Ultravision hydrogen peroxide(Thermo kit/Ultravision LP detection system)を利用してペルオキシダーゼ(peroxidase)活性を阻害した。Ultravision blockバッファーを常温で10分間反応させた後、当該1次抗体を処理し、4℃でオーバーナイト処理した。一次抗体は、それぞれTXNDC5(Abcam,Ab155684)、PRRC1(Abcam/ab12544)、S100A11(Abcam/ab97329)、Galectin 1(Abcam,Ab108389)、Filamin A(Millipore/MAB1680)、eIF5-A(Abcam/ab32014)、Annexin A2(Cell singnaling/8235)、FABP5(Abcam/ab37267)を使用した。一次抗体エンハンサー(Primary antibody enhancer)を常温で10分間処理した後、HRP polymerを光遮断状態で常温で15分間反応させた。HRP-polymerを除去した後、PRRC1を除いたすべての組織をAEC(Spring,ASS-125)、PRRC1は、DAB(Thermo,TA-125-HDX)を1分間処理した。Mayer’s hematoxylinで常温で組織を染色し、脱水させた後、Canada balsam mixed Xyleneでmounting進行後、組織を顕微鏡で観察した。
前記IHC結果で選別された前記タンパク質のうち3種(TXNDC5,PRRC1,S100A11)に対してsiRNAを利用して各遺伝子発現をノックダウン(knock-down)させた後、傷跡で過度に発現するコラーゲンおよび線維芽細胞増殖関連タンパク質などの発現を分析した。
本発明の態様を以下の項にさらに記載する:
[項1]
TXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の活性を抑制したり、または前記一つ以上のタンパク質をコードする遺伝子の発現を抑制する物質を有効成分として含む、ケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)の予防または治療用薬学的組成物。
[項2]
前記有効成分は、shRNA、siRNA、miRNA、アンチセンスオリゴヌクレオチド、リボザイム(ribozyme)、Crispr-cas9、DNAzyme、PNA(peptide nucleic acids)、ペプチド、抗体、アプタマー、天然抽出物または化学物質であることを特徴とする上記項1に記載のケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)の予防または治療用薬学的組成物。
[項3]
前記有効成分は、前記遺伝子の発現を抑制するshRNA、siRNA、miRNAまたはアンチセンスオリゴヌクレオチドであることを特徴とする上記項2に記載のケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)の予防または治療用薬学的組成物。
[項4]
(a)ケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)患者に由来した組織に試験物質を処理する段階;および
(b)前記試験物質が処理された組織または細胞で TXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の活性または前記タンパク質をコードする遺伝子の発現量を分析する段階であって、正常組織での前記タンパク質の活性またはこれをコードする遺伝子の発現様相と異なる場合、前記試験物質をケロイドまたは肥厚性瘢痕の予防または治療物質と判断する、ケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)の予防または治療物質のスクリーニング方法。
[項5]
TXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上の遺伝子、またはTXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の発現量を測定する物質を含む、ケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)診断用組成物。
[項6]
ケロイドまたは肥厚性瘢痕を有したり予想される個体から得た試料でTXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上の遺伝子、またはTXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の発現量を測定する段階;および
前記測定結果を正常個体の試料での前記遺伝子またはタンパク質の発現量と比較する段階;を含むケロイドまたは肥厚性瘢痕の診断方法。
[項7]
ケロイドまたは肥厚性パヌルルル有する個体に(a)有効成分としてTXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上の遺伝子の発現を抑制したり、またはTXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の活性を抑制する物質を含む薬学的組成物を投与することを含む、ケロイド疾患または肥厚性瘢痕を有する個体を治療する方法。
Claims (7)
- TXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の活性を抑制したり、または前記一つ以上のタンパク質をコードする遺伝子の発現を抑制する物質を有効成分として含む、ケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)の予防または治療用薬学的組成物。
- 前記有効成分は、shRNA、siRNA、miRNA、アンチセンスオリゴヌクレオチド、リボザイム(ribozyme)、Crispr-cas9、DNAzyme、PNA(peptide nucleic acids)、ペプチド、抗体、アプタマー、天然抽出物または化学物質であることを特徴とする請求項1に記載のケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)の予防または治療用薬学的組成物。
- 前記有効成分は、前記遺伝子の発現を抑制するshRNA、siRNA、miRNAまたはアンチセンスオリゴヌクレオチドであることを特徴とする請求項2に記載のケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)の予防または治療用薬学的組成物。
- (a)ケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)患者に由来した組織に試験物質を処理する段階;および
(b)前記試験物質が処理された組織または細胞で TXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の活性または前記タンパク質をコードする遺伝子の発現量を分析する段階であって、正常組織での前記タンパク質の活性またはこれをコードする遺伝子の発現様相と異なる場合、前記試験物質をケロイドまたは肥厚性瘢痕の予防または治療物質と判断する、ケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)の予防または治療物質のスクリーニング方法。 - TXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上の遺伝子、またはTXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の発現量を測定する物質を含む、ケロイド(Keloid)または肥厚性瘢痕(Hypertrophic scar)診断用組成物。
- ケロイドまたは肥厚性瘢痕を有したり予想される個体から得た試料でTXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上の遺伝子、またはTXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の発現量を測定する段階;および
前記測定結果を正常個体の試料での前記遺伝子またはタンパク質の発現量と比較する段階;を含むケロイドまたは肥厚性瘢痕の診断方法。 - ケロイドまたは肥厚性パヌルルル有する個体に(a)有効成分としてTXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上の遺伝子の発現を抑制したり、またはTXNDC5、PRRC1、S100A11、Galectin 1、Filamin A、eIF-5A、Annexin A2およびFABP5よりなる群から選ばれる一つ以上のタンパク質の活性を抑制する物質を含む薬学的組成物を投与することを含む、ケロイド疾患または肥厚性瘢痕を有する個体を治療する方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0117157 | 2019-09-24 | ||
KR1020190117157A KR102100163B1 (ko) | 2019-09-24 | 2019-09-24 | 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물 |
PCT/KR2019/017039 WO2021060624A1 (ko) | 2019-09-24 | 2019-12-04 | 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물 |
JP2020509485A JP7132646B2 (ja) | 2019-09-24 | 2019-12-04 | ケロイドまたは肥厚性瘢痕の予防または治療用組成物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020509485A Division JP7132646B2 (ja) | 2019-09-24 | 2019-12-04 | ケロイドまたは肥厚性瘢痕の予防または治療用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022166228A true JP2022166228A (ja) | 2022-11-01 |
JP7323229B2 JP7323229B2 (ja) | 2023-08-08 |
Family
ID=70224654
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020509485A Active JP7132646B2 (ja) | 2019-09-24 | 2019-12-04 | ケロイドまたは肥厚性瘢痕の予防または治療用組成物 |
JP2022130528A Active JP7323229B2 (ja) | 2019-09-24 | 2022-08-18 | ケロイドまたは肥厚性瘢痕の予防または治療用組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020509485A Active JP7132646B2 (ja) | 2019-09-24 | 2019-12-04 | ケロイドまたは肥厚性瘢痕の予防または治療用組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20210388352A1 (ja) |
EP (1) | EP3824892A4 (ja) |
JP (2) | JP7132646B2 (ja) |
KR (1) | KR102100163B1 (ja) |
CN (1) | CN112839664A (ja) |
WO (1) | WO2021060624A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102100163B1 (ko) | 2019-09-24 | 2020-04-13 | 테고사이언스 (주) | 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물 |
CN115616215A (zh) * | 2021-07-13 | 2023-01-17 | 上海交通大学医学院附属第九人民医院 | 一种瘢痕诊断试剂及其应用 |
CN114249839A (zh) * | 2021-12-31 | 2022-03-29 | 山东林森生物制品股份有限公司 | 一种ⅲ型胶原蛋白的融合蛋白、表达系统、药物组合物及应用 |
CN114533877B (zh) * | 2022-03-09 | 2023-07-04 | 上海交通大学医学院附属第九人民医院 | Bag3抑制剂在制备治疗瘢痕产品中的用途 |
US11859188B2 (en) * | 2022-03-28 | 2024-01-02 | Chi-Hua Fundation | DNA aptamer, pharmaceutical composition comprising same, method for inhibiting catalytic ability of TXNDC5, and method for preventing or treating organ fibrosis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150224132A1 (en) * | 2014-02-07 | 2015-08-13 | Effector Therapeutics, Inc. | Compositions and methods for treating fibrotic disease |
JP2017513922A (ja) * | 2014-03-11 | 2017-06-01 | ワン、イウェンWANG, Yi−Wen | 瘢痕形成を軽減する医薬組成物及び方法 |
WO2018078624A1 (en) * | 2016-10-25 | 2018-05-03 | Ticure Ltd. | Fabp4 as a therapeutic target in skin diseases |
US20180326094A1 (en) * | 2016-01-05 | 2018-11-15 | Industry-University Cooperation Foundation Hanyang University | Composition for preventing or treating keloid or hypertrophic scars |
US20190011457A1 (en) * | 2016-01-15 | 2019-01-10 | Tego Science Inc. | Biomarkers for diagnosing keloid skin or keloid scar, and use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
EP1147204A1 (en) | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのrna干渉経路遺伝子 |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
WO2007027509A2 (en) * | 2005-08-31 | 2007-03-08 | Biogen Idec Ma Inc. | Evaluating and treating scleroderma |
PL2670411T3 (pl) | 2011-02-02 | 2019-09-30 | Excaliard Pharmaceuticals, Inc. | Związki antysensowne ukierunkowane na czynnik wzrostu tkanki łącznej (ctgf) do leczenia bliznowców lub blizn przerostowych |
KR101505294B1 (ko) | 2013-06-19 | 2015-03-23 | 강릉원주대학교산학협력단 | 켈로이드 또는 흉터 형성을 감소시키기 위한 조성물 |
WO2015019124A1 (en) * | 2013-08-05 | 2015-02-12 | Societe De Developpement Et De Recherche Industrielle | Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids |
KR101943434B1 (ko) * | 2015-06-26 | 2019-01-30 | 순천향대학교 산학협력단 | 켈로이드 조직 진단용 바이오 마커 조성물 및 이를 포함하는 키트 |
KR102100163B1 (ko) | 2019-09-24 | 2020-04-13 | 테고사이언스 (주) | 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물 |
-
2019
- 2019-09-24 KR KR1020190117157A patent/KR102100163B1/ko active IP Right Grant
- 2019-12-04 JP JP2020509485A patent/JP7132646B2/ja active Active
- 2019-12-04 US US16/639,760 patent/US20210388352A1/en not_active Abandoned
- 2019-12-04 EP EP19926727.9A patent/EP3824892A4/en active Pending
- 2019-12-04 CN CN201980031715.4A patent/CN112839664A/zh active Pending
- 2019-12-04 WO PCT/KR2019/017039 patent/WO2021060624A1/ko unknown
-
2022
- 2022-08-18 JP JP2022130528A patent/JP7323229B2/ja active Active
- 2022-11-21 US US17/990,757 patent/US11946051B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150224132A1 (en) * | 2014-02-07 | 2015-08-13 | Effector Therapeutics, Inc. | Compositions and methods for treating fibrotic disease |
JP2017513922A (ja) * | 2014-03-11 | 2017-06-01 | ワン、イウェンWANG, Yi−Wen | 瘢痕形成を軽減する医薬組成物及び方法 |
US20180326094A1 (en) * | 2016-01-05 | 2018-11-15 | Industry-University Cooperation Foundation Hanyang University | Composition for preventing or treating keloid or hypertrophic scars |
US20190011457A1 (en) * | 2016-01-15 | 2019-01-10 | Tego Science Inc. | Biomarkers for diagnosing keloid skin or keloid scar, and use thereof |
WO2018078624A1 (en) * | 2016-10-25 | 2018-05-03 | Ticure Ltd. | Fabp4 as a therapeutic target in skin diseases |
Non-Patent Citations (1)
Title |
---|
J MOL HIST., vol. 46, JPN6022000174, 2015, pages 357 - 364, ISSN: 0005100678 * |
Also Published As
Publication number | Publication date |
---|---|
JP7323229B2 (ja) | 2023-08-08 |
JP2022512516A (ja) | 2022-02-07 |
KR102100163B1 (ko) | 2020-04-13 |
CN112839664A (zh) | 2021-05-25 |
EP3824892A4 (en) | 2023-06-14 |
JP7132646B2 (ja) | 2022-09-07 |
US11946051B2 (en) | 2024-04-02 |
WO2021060624A1 (ko) | 2021-04-01 |
US20230124032A1 (en) | 2023-04-20 |
US20210388352A1 (en) | 2021-12-16 |
EP3824892A1 (en) | 2021-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7323229B2 (ja) | ケロイドまたは肥厚性瘢痕の予防または治療用組成物 | |
US9642873B2 (en) | Combinations of TGFβ and COX-2 inhibitors and methods for their therapeutic application | |
JP6837963B2 (ja) | Mir−29模倣物およびその使用 | |
US10864283B2 (en) | Composition for preventing or treating keloid or hypertrophic scars | |
Chuang et al. | Functional role of the long noncoding RNA X-inactive specific transcript in leiomyoma pathogenesis | |
US12006501B2 (en) | Composition of drug targets and method of using thereof | |
JP2003504418A (ja) | ホルモン制御腫瘍のアンチセンス治療法 | |
US10260067B2 (en) | Enhancing dermal wound healing by downregulating microRNA-26a | |
CN110904104B (zh) | 人hist1h2bk基因的用途及相关产品 | |
JP2020508699A (ja) | 男性型脱毛標的遺伝子の発現を抑制する非対称siRNA | |
JP6238319B2 (ja) | 創傷または線維症の治療剤 | |
JP2015533085A (ja) | Rna活性及び血管透過性の調節 | |
CN112725436A (zh) | 一种人circMKLN1基因的用途及相关产品 | |
KR20190084902A (ko) | Dlk1-Dio3 클러스터에 위치한 miRNA 또는 이의 변이체를 유효성분으로 포함하는 근육질환 또는 악액질의 예방 또는 치료용 약학 조성물 | |
EP2970978A1 (en) | Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing | |
CN110819631B (zh) | 人dmbx1基因的用途及相关产品 | |
CN111041028B (zh) | 人ttll4基因的用途及相关产品 | |
CN111763671B (zh) | 一种靶向组蛋白去甲基化酶KDM5B的siRNA及用途 | |
JP2012508224A (ja) | 脂肪生成の調節のためのPlac8活性の阻害剤の使用 | |
Remes | Therapeutic transcription factor decoy oligodeoxynucleotides for Marfan syndrome and heart failure | |
EP2308892A1 (en) | Use of siRNA targetting Sipa1l1 for the reduction of adipogenesis | |
Li et al. | M3 subtype of muscarinic acetylcholine receptor inhibits cardiac fibrosis via targeting microRNA-29b/beta-site app cleaving enzyme 1 axis | |
CN113917144A (zh) | 人sh2d2a基因的用途及相关产品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220830 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220830 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230704 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230720 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7323229 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |